Eupraxia Pharmaceuticals announced encouraging data from its ongoing Phase 1b/2a RESOLVE trial evaluating EP-104GI for eosinophilic esophagitis (EoE). The data showed that patients receiving 20 injections of EP-104GI experienced significant improvements in the Eosinophilic Esophagitis Endoscopic Reference Score (EREFS), indicating reduced inflammation and fibrosis in the esophagus. This dosing regimen is now being studied in the placebo-controlled Phase 2b trial, with top-line results expected in Q4 2026. These findings suggest EP-104GI could offer a promising new treatment for EoE, a condition causing esophageal inflammation and swallowing difficulties.
Dycom Industries reported a record first quarter with contract revenues up 56.1% to $1.965 billion and adjusted net income nearly doubling to $134.3 million. The company raised its full-year fiscal 2027 revenue outlook to $7.38-$7.65 billion, driven ...
BrewDog, part of Tilray Brands, is rolling out a major summer campaign across the UK tied to the global football tournament. The campaign features a "Win a Year of Beer" contest with special cans hidden in over 2.8 million packs at major retailers, p...
Atea Pharmaceuticals announced Phase 1 results indicating their Hepatitis C treatment regimen, combining bemnifosbuvir and ruzasvir, has a low risk of drug-drug interactions with common medications like omeprazole and rosuvastatin. This supports easi...
Girard Sharp LLP is investigating potential securities claims for former Discover investors who received Capital One shares after Capital One acquired Discover in May 2025. Since the merger, Capital One's stock price has declined, leading to possible...
Sunshine Silver, a mining and refining company based in Idaho, is preparing for a $2.32 billion initial public offering on the New York Stock Exchange. The company aims to raise up to $330 million by selling 20 million shares priced between $13.50 an...
